| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
214344 Anheuser-Busch Companies, LLC /ˈænhaɪzər ˈbʊʃ/ is an American brewing company headquartered in St.
Advanced Compliance Laboratory is a Hillsborough, NJ-based company in the Software and Internet sector.
NCN is a new breed of tower company, offering neutral hosting of networks in addition to traditional attachment. As carriers seek to shorten the time to market of coverage and capacity, NCN offers network Quality of Service at a lower bit/cost than traditional deployment models.
Jeda Technologies is a Mountain View, CA-based company in the Software and Internet sector.